Research programme: anti-cancer polymeric micelle therapeutics - Samyang Biopharmaceuticals Corporation

Drug Profile

Research programme: anti-cancer polymeric micelle therapeutics - Samyang Biopharmaceuticals Corporation

Alternative Names: B 6036; B 6061

Latest Information Update: 03 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Samyang Biopharmaceuticals Corporation
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 03 Mar 2016 Preclinical trials in Cancer in South Korea (Parenteral) before March 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top